Capitolis Liquid Global Markets LLC Sells 733,200 Shares of Bristol Myers Squibb Company $BMY

Capitolis Liquid Global Markets LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY) by 78.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 206,000 shares of the biopharmaceutical company’s stock after selling 733,200 shares during the period. Capitolis Liquid Global Markets LLC’s holdings in Bristol Myers Squibb were worth $9,291,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Harbor Capital Advisors Inc. boosted its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the last quarter. Total Investment Management Inc. acquired a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $40,000. Finally, Bank of Jackson Hole Trust raised its holdings in shares of Bristol Myers Squibb by 352.2% in the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 810 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $59.02 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company’s fifty day simple moving average is $58.24 and its 200 day simple moving average is $51.46. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. HSBC restated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.